{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:53:19Z","timestamp":1790909599052,"version":"4.1.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25K10874"],"award-info":[{"award-number":["25K10874"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background\/Objectives<\/jats:title>\n                    <jats:p>This network meta-analysis involved nine randomized controlled trials, comprising 595 participants (average age = 37.8 years, 55.3% female, 83.9% schizophrenia spectrum disorders), evaluating the comparative risk\u2013benefit profiles of glucagon-like peptide-1 receptor agonists in individuals with obesity comorbid with mental illness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Subjects\/Methods<\/jats:title>\n                    <jats:p>Outcomes included body weight (primary); body mass index (BMI); waist circumference; blood-based measures, including fasting plasma glucose, hemoglobin A1c (HbA1c), total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides; systolic and diastolic blood pressure; death; all-cause discontinuation; adverse event-related discontinuation; serious adverse events (SAEs), injection site-related adverse events, headache, dizziness, nausea, vomiting, constipation, and diarrhea; psychiatric hospitalization; and changes in overall schizophrenia symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Treatment arms comprised subcutaneous exenatide (S-EXE)(twice-daily [BID]\/once-weekly [QW]), subcutaneous liraglutide (S-LIR)(once-daily [QD]), and subcutaneous semaglutide (S-SEM)(QW), alongside a control group (placebo, k\u2009=\u20098; non-placebo, k\u2009=\u20091). S-LIR(QD) and S-SEM(QW) were significantly associated with reduced body weight compared with control, with standardized mean differences (95% confidence intervals) of \u22120.945 (\u2009\u2212\u20091.784 to \u22120.106) and \u22122.101 (\u2009\u2212\u20092.978 to \u22121.224), respectively. S-LIR(QD) was associated with waist circumference and HbA1c level reductions, lower SAE incidences, and higher nausea, vomiting, and constipation incidences compared with the control. S-SEM(QW) was associated with reduced BMI, waist circumference, fasting plasma glucose, and HbA1c levels, and higher nausea, vomiting, and constipation compared with the control. Each drug did not differ from control regarding other outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>S-SEM(QW) may be the preferred treatment option, given its largest estimated effects versus control on body weight; however, its comparative ranking is uncertain due to sparse networks, substantial heterogeneity, and predominant indirect evidence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41398-026-04253-6","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:16:58Z","timestamp":1783531018000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Glucagon-like peptide-1 receptor agonists for weight management in mental illness: a network meta-analysis"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9237-2236","authenticated-orcid":false,"given":"Taro","family":"Kishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0848-302X","authenticated-orcid":false,"given":"Toshikazu","family":"Ikuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Sakuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7032-878X","authenticated-orcid":false,"given":"Masakazu","family":"Hatano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Takayanagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3189-6076","authenticated-orcid":false,"given":"Nakao","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"4253_CR1","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/S2215-0366(25)00031-8","volume":"12","author":"RA McCutcheon","year":"2025","unstructured":"McCutcheon RA, Pillinger T, Varvari I, Halstead S, Ayinde OO, Crossley NA, et al. INTEGRATE: international guidelines for the algorithmic treatment of schizophrenia. Lancet Psychiatry. 2025;12:384\u201394.","journal-title":"Lancet Psychiatry"},{"key":"4253_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0269881119889296","volume":"34","author":"TR Barnes","year":"2020","unstructured":"Barnes TR, Drake R, Paton C, Cooper SJ, Deakin B, Ferrier IN, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2020;34:3\u201378.","journal-title":"J Psychopharmacol"},{"key":"4253_CR3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","volume":"13","author":"F Rubino","year":"2025","unstructured":"Rubino F, Cummings DE, Eckel RH, Cohen RV, Wilding JPH, Brown WA, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;13:221\u201362.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4253_CR4","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","volume":"177","author":"GA Keepers","year":"2020","unstructured":"Keepers GA, Fochtmann LJ, Anzia JM, Benjamin S, Lyness JM, Mojtabai R, et al. The American psychiatric association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177:868\u201372.","journal-title":"Am J Psychiatry"},{"key":"4253_CR5","doi-asserted-by":"publisher","first-page":"e300836","DOI":"10.1136\/bmjment-2023-300836","volume":"26","author":"C Zarbo","year":"2023","unstructured":"Zarbo C, Rota M, Calza S, Crouter SE, Ekelund U, Barlati S, et al. Ecological monitoring of physical activity, emotions and daily life activities in schizophrenia: the DiAPAson study. BMJ Ment Health. 2023;26:e300836.","journal-title":"BMJ Ment Health"},{"key":"4253_CR6","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1053\/j.gastro.2022.08.045","volume":"163","author":"E Grunvald","year":"2022","unstructured":"Grunvald E, Shah R, Hernaez R, Chandar AK, Pickett-Blakely O, Teigen LM, et al. AGA clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology. 2022;163:1198\u2013225.","journal-title":"Gastroenterology"},{"key":"4253_CR7","doi-asserted-by":"crossref","unstructured":"Celletti F, Farrar J, De Regil L. World health organization guideline on the use and indications of glucagon-like peptide-1 therapies for the treatment of obesity in adults. JAMA. 2026;335:434\u201338.","DOI":"10.1001\/jama.2025.24288"},{"key":"4253_CR8","doi-asserted-by":"publisher","first-page":"e2821","DOI":"10.1002\/hup.2821","volume":"37","author":"A Miola","year":"2022","unstructured":"Miola A, Fornaro M, Sambataro F, Solmi M. Melatonin and melatonin-agonists for metabolic syndrome components in patients treated with antipsychotics: A systematic review and meta-analysis. Hum Psychopharmacol. 2022;37:e2821.","journal-title":"Hum Psychopharmacol"},{"key":"4253_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.genhosppsych.2024.06.003","volume":"90","author":"NC Hegde","year":"2024","unstructured":"Hegde NC, Mishra A, Maiti R, Mishra BR, Mohapatra D, Srinivasan A. Pharmacological interventions for antipsychotic-induced weight gain in schizophrenia: A network meta-analysis. Gen Hosp Psychiatry. 2024;90:12\u201321.","journal-title":"Gen Hosp Psychiatry"},{"key":"4253_CR10","doi-asserted-by":"publisher","first-page":"152632","DOI":"10.1016\/j.comppsych.2025.152632","volume":"143","author":"Z Goetz-Kundera","year":"2025","unstructured":"Goetz-Kundera Z, Przekopinska B, Walichniewicz P, Niewada M, Lew-Starowicz M. Comparative effects of pharmacological treatment for weight gain in patients treated with antipsychotics. A systematic review and network meta-analysis. Compr Psychiatry. 2025;143:152632.","journal-title":"Compr Psychiatry"},{"key":"4253_CR11","doi-asserted-by":"publisher","first-page":"S307","DOI":"10.37765\/ajmc.2022.89294","volume":"28","author":"A Amaro","year":"2022","unstructured":"Amaro A, Kaplan M, Massie DC. Managed care considerations of weight management interventions for obesity. Am J Manag Care. 2022;28:S307\u2013S18.","journal-title":"Am J Manag Care"},{"key":"4253_CR12","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s40618-024-02361-y","volume":"47","author":"M Chianelli","year":"2024","unstructured":"Chianelli M, Busetto L, Vettor R, Annibale B, Paoletta A, Papini E, et al. Italian guidelines for the management of adult individuals with overweight and obesity and metabolic comorbidities that are resistant to behavioral treatment. J Endocrinol Invest. 2024;47:1361\u201371.","journal-title":"J Endocrinol Invest"},{"key":"4253_CR13","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1038\/s41591-025-03765-w","volume":"31","author":"B McGowan","year":"2025","unstructured":"McGowan B, Ciudin A, Baker JL, Busetto L, Dicker D, Fruhbeck G, et al. Framework for the pharmacological treatment of obesity and its complications from the European association for the study of obesity (EASO). Nat Med. 2025;31:3229\u201332.","journal-title":"Nat Med"},{"key":"4253_CR14","doi-asserted-by":"publisher","first-page":"S167","DOI":"10.2337\/dc25-S008","volume":"48","author":"American Diabetes Association Professional Practice C.","year":"2025","unstructured":"American Diabetes Association Professional Practice C. 8. obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes-2025. Diabetes Care. 2025;48:S167\u2013S80.","journal-title":"Diabetes Care"},{"key":"4253_CR15","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1038\/s41591-025-03978-z","volume":"31","author":"B McGowan","year":"2025","unstructured":"McGowan B, Ciudin A, Baker JL, Busetto L, Dicker D, Fruhbeck G, et al. A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults. Nat Med. 2025;31:3317\u201329.","journal-title":"Nat Med"},{"key":"4253_CR16","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S2215-0366(25)00129-4","volume":"12","author":"D Siskind","year":"2025","unstructured":"Siskind D, Baker A, Arnautovska U, Warren N, Russell A, DeMonte V, et al. Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-centre, participant and investigator- blinded, randomised controlled trial in Australia. Lancet Psychiatry. 2025;12:493\u2013503.","journal-title":"Lancet Psychiatry."},{"key":"4253_CR17","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1001\/jamapsychiatry.2025.2332","volume":"82","author":"AA Ganeshalingam","year":"2025","unstructured":"Ganeshalingam AA, Uhrenholt N, Arnfred S, Gaede P, During S, Stenager EN, et al. Semaglutide treatment of antipsychotic-treated patients with schizophrenia, prediabetes, and obesity: the HISTORI randomized clinical trial. JAMA Psychiatry. 2025;82:1065\u201374.","journal-title":"JAMA Psychiatry"},{"key":"4253_CR18","doi-asserted-by":"crossref","unstructured":"Sass MR, Klausen MK, Schwarz CR, Rasmussen L, Giver MEB, Hviid M, et al. Semaglutide and early-stage metabolic abnormalities in individuals with schizophrenia spectrum disorders: a randomized clinical trial. JAMA Psychiatry. 2026;83:128\u201338.","DOI":"10.1001\/jamapsychiatry.2025.3639"},{"key":"4253_CR19","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777\u201384.","journal-title":"Ann Intern Med"},{"key":"4253_CR20","unstructured":"Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. Cochrane handbook for systematic reviews ofinterventions version 6.5 (updated August2024). Cochrane. 2024. https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook."},{"key":"4253_CR21","unstructured":"FDA. U.S. Food and Drug Administration. https:\/\/www.fdagov\/."},{"key":"4253_CR22","unstructured":"EMA. European Medicines Agency. https:\/\/www.emaeuropaeu\/en\/homepage."},{"key":"4253_CR23","unstructured":"PMDA. Pharmaceuticals and Medical Devices Agency. https:\/\/www.pmdagojp\/english\/indexhtml."},{"key":"4253_CR24","unstructured":"ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/."},{"key":"4253_CR25","unstructured":"EU-CTR. https:\/\/www.emaeuropaeu\/en\/human-regulatory-overview\/research-development\/clinical-trials-human-medicines\/clinical-trials-regulation."},{"key":"4253_CR26","unstructured":"WHO-ICTRP. http:\/\/www.whoint\/ictrp\/network\/trds\/en."},{"key":"4253_CR27","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/acps.12526","volume":"133","author":"SD Ostergaard","year":"2016","unstructured":"Ostergaard SD, Lemming OM, Mors O, Correll CU, Bech P. PANSS-6: a brief rating scale for the measurement of severity in schizophrenia. Acta Psychiatr Scand. 2016;133:436\u201344.","journal-title":"Acta Psychiatr Scand"},{"key":"4253_CR28","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","volume":"10","author":"J Overall","year":"1962","unstructured":"Overall J, Gorham D. The brief psychiatric rating scale. Psychol Rep. 1962;10:799\u2013812.","journal-title":"Psychol Rep"},{"key":"4253_CR29","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261\u201376.","journal-title":"Schizophr Bull"},{"key":"4253_CR30","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177\u201388.","journal-title":"Control Clin Trials"},{"key":"4253_CR31","unstructured":"R\u00fccker G, Schwarzer G, Krahn U, K\u00f6nig J. netmeta: Network Meta-Analysis using Frequentist Methods, 2017. R package version 0.9-5. https:\/\/CRAN.R-project.org\/package=netmeta."},{"key":"4253_CR32","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/sim.3767","volume":"29","author":"S Dias","year":"2010","unstructured":"Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 2010;29:932\u201344.","journal-title":"Stat Med"},{"key":"4253_CR33","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1002\/sim.6188","volume":"33","author":"D Jackson","year":"2014","unstructured":"Jackson D, Barrett JK, Rice S, White IR, Higgins JP. A design-by-treatment interaction model for network meta-analysis with random inconsistency effects. Stat Med. 2014;33:3639\u201354.","journal-title":"Stat Med"},{"key":"4253_CR34","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/jrsm.1054","volume":"3","author":"G van Valkenhoef","year":"2012","unstructured":"van Valkenhoef G, Lu G, de Brock B, Hillege H, Ades AE, Welton NJ. Automating network meta-analysis. Res Synth Methods. 2012;3:285\u201399.","journal-title":"Res Synth Methods"},{"key":"4253_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-025-03439-8","volume":"15","author":"T Kishi","year":"2025","unstructured":"Kishi T, Ikuta T, Citrome L, Sakuma K, Hatano M, Hamanaka S, et al. Comparative efficacy and safety of daridorexant, lemborexant, and suvorexant for insomnia: a systematic review and network meta-analysis. Transl Psychiatry. 2025;15:211.","journal-title":"Transl Psychiatry"},{"key":"4253_CR36","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(08)61206-4","volume":"372","author":"DJ Drucker","year":"2008","unstructured":"Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372:1240\u201350.","journal-title":"Lancet"},{"key":"4253_CR37","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1210\/jc.2010-2081","volume":"96","author":"T Blevins","year":"2011","unstructured":"Blevins T, Pullman J, Malloy J, Yan P, Taylor K, Schulteis C, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96:1301\u201310.","journal-title":"J Clin Endocrinol Metab"},{"key":"4253_CR38","doi-asserted-by":"publisher","first-page":"5043","DOI":"10.1111\/dom.70698","volume":"28","author":"J Vienghirun","year":"2026","unstructured":"Vienghirun J, Sawangjit R, Suttiruksa S, Chaiyakunapruk N, Jinathongthai P, Khunti K, et al. GLP-1 receptor\/dual agonists for weight loss: a systematic review and network meta-analysis of RCTs. Diabetes Obes Metab. 2026;28:5043\u201357.","journal-title":"Diabetes Obes Metab"},{"key":"4253_CR39","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1111\/dom.13167","volume":"20","author":"DJ Siskind","year":"2018","unstructured":"Siskind DJ, Russell AW, Gamble C, Winckel K, Mayfield K, Hollingworth S, et al. Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: A randomized controlled trial (CODEX). Diabetes Obes Metab. 2018;20:1050\u20135.","journal-title":"Diabetes Obes Metab"},{"key":"4253_CR40","doi-asserted-by":"publisher","first-page":"e99682","DOI":"10.1371\/journal.pone.0099682","volume":"9","author":"G Salanti","year":"2014","unstructured":"Salanti G, Del Giovane C, Chaimani A, Caldwell DM, Higgins JP. Evaluating the quality of evidence from a network meta-analysis. PLoS ONE. 2014;9:e99682.","journal-title":"PLoS ONE"},{"key":"4253_CR41","doi-asserted-by":"publisher","first-page":"e1003082","DOI":"10.1371\/journal.pmed.1003082","volume":"17","author":"A Nikolakopoulou","year":"2020","unstructured":"Nikolakopoulou A, Higgins JPT, Papakonstantinou T, Chaimani A, Del Giovane C, Egger M, et al. CINeMA: An approach for assessing confidence in the results of a network meta-analysis. PLoS Med. 2020;17:e1003082.","journal-title":"PLoS Med"},{"key":"4253_CR42","first-page":"e1080","volume":"16","author":"T Papakonstantinou","year":"2020","unstructured":"Papakonstantinou T, Nikolakopoulou A, Higgins JPT, Egger M, Salanti G. CINeMA: Software for semiautomated assessment of the confidence in the results of network meta-analysis. Campbell Systematic Reviews. 2020;16:e1080.","journal-title":"Campbell Systematic Reviews"},{"key":"4253_CR43","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/dom.12795","volume":"19","author":"PL Ishoy","year":"2017","unstructured":"Ishoy PL, Knop FK, Broberg BV, Bak N, Andersen UB, Jorgensen NR, et al. Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial. Diabetes Obes Metab. 2017;19:162\u201371.","journal-title":"Diabetes Obes Metab"},{"key":"4253_CR44","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1001\/jamapsychiatry.2017.1220","volume":"74","author":"JR Larsen","year":"2017","unstructured":"Larsen JR, Vedtofte L, Jakobsen MSL, Jespersen HR, Jakobsen MI, Svensson CK, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial. JAMA Psychiatry. 2017;74:719\u201328.","journal-title":"JAMA Psychiatry"},{"key":"4253_CR45","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/JCP.0000000000001803","volume":"44","author":"SL McElroy","year":"2024","unstructured":"McElroy SL, Guerdjikova AI, Blom TJ, Mori N, Romo-Nava F. Liraglutide in obese or overweight individuals with stable bipolar disorder. J Clin Psychopharmacol. 2024;44:89\u201395.","journal-title":"J Clin Psychopharmacol"},{"key":"4253_CR46","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jad.2025.04.046","volume":"382","author":"LR Patino","year":"2025","unstructured":"Patino LR, Strawn JR, Adler CM, Blom TJ, Welge JA, DelBello MP. A double-blind, placebo-controlled trial of exenatide for the treatment of olanzapine-related weight gain in obese and overweight adults. J Affect Disord. 2025;382:116\u201322.","journal-title":"J Affect Disord"},{"key":"4253_CR47","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1111\/dom.14334","volume":"23","author":"CA Whicher","year":"2021","unstructured":"Whicher CA, Price HC, Phiri P, Rathod S, Barnard-Kelly K, Ngianga K, et al. The use of liraglutide 3.0\u2009mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: results of a pilot randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2021;23:1262\u201371.","journal-title":"Diabetes Obes Metab"},{"key":"4253_CR48","doi-asserted-by":"publisher","first-page":"4146","DOI":"10.1038\/s41380-020-00946-6","volume":"26","author":"T Kishi","year":"2021","unstructured":"Kishi T, Ikuta T, Matsuda Y, Sakuma K, Okuya M, Mishima K, et al. Mood stabilizers and\/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials. Mol Psychiatry. 2021;26:4146\u201357.","journal-title":"Mol Psychiatry"},{"key":"4253_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-024-02881-4","volume":"14","author":"C Grosu","year":"2024","unstructured":"Grosu C, Klauser P, Dwir D, Khadimallah I, Aleman-Gomez Y, Laaboub N, et al. Associations between antipsychotics-induced weight gain and brain networks of impulsivity. Transl Psychiatry. 2024;14:162.","journal-title":"Transl Psychiatry"},{"key":"4253_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-025-03429-w","volume":"15","author":"A Yehia","year":"2025","unstructured":"Yehia A, Melhuish Beaupre LM, Ho MC, Biernnacka JM, Frye MA, Abulseoud OA. Ferroptosis as a potential molecular mechanism of bipolar disorder. Transl Psychiatry. 2025;15:205.","journal-title":"Transl Psychiatry"},{"key":"4253_CR51","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1038\/s41380-025-03337-x","volume":"31","author":"B Deakin","year":"2026","unstructured":"Deakin B, Liddle E, Rathnaiah M, Gregory CC, Katshu MZ, Williams G, et al. Investigating the disturbance in cortical glutamate and GABA function in psychosis and its origins and consequences. Mol Psychiatry. 2026;31:1983\u201391.","journal-title":"Mol Psychiatry"},{"key":"4253_CR52","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1007\/s00213-020-05629-2","volume":"237","author":"T Kishi","year":"2020","unstructured":"Kishi T, Miyake N, Okuya M, Sakuma K, Iwata N. N-acetylcysteine as an adjunctive treatment for bipolar depression and major depressive disorder: a systematic review and meta-analysis of double-blind, randomized placebo-controlled trials. Psychopharmacology (Berl). 2020;237:3481\u20137.","journal-title":"Psychopharmacology (Berl)"},{"key":"4253_CR53","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/pcn.13502","volume":"77","author":"T Kishi","year":"2023","unstructured":"Kishi T, Sakuma K, Hatano M, Iwata N. N-acetylcysteine for schizophrenia: A systematic review and meta-analysis. Psychiatry Clin Neurosci. 2023;77:119\u201321.","journal-title":"Psychiatry Clin Neurosci"},{"key":"4253_CR54","doi-asserted-by":"publisher","first-page":"108831","DOI":"10.1016\/j.sleep.2026.108831","volume":"141","author":"FH van Bruggen","year":"2026","unstructured":"van Bruggen FH, McIntyre RS. Obstructive sleep apnea as a potential mechanistic link between second-generation antipsychotics and metabolic syndrome: a narrative review. Sleep Med. 2026;141:108831.","journal-title":"Sleep Med"},{"key":"4253_CR55","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.2337\/dc26-S002","volume":"49","author":"ADA.","year":"2026","unstructured":"ADA. Standards of care in diabetes\u20142026 (American Diabetes Association). Diabetes Care. 2026;49:S27\u2013S49.","journal-title":"Diabetes Care"},{"key":"4253_CR56","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41573-019-0053-0","volume":"19","author":"DJ Drucker","year":"2020","unstructured":"Drucker DJ. Advances in oral peptide therapeutics. Nat Rev Drug Discov. 2020;19:277\u201389.","journal-title":"Nat Rev Drug Discov"},{"key":"4253_CR57","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.euroneuro.2019.02.003","volume":"29","author":"I Pacchiarotti","year":"2019","unstructured":"Pacchiarotti I, Tiihonen J, Kotzalidis GD, Verdolini N, Murru A, Goikolea JM, et al. Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: A systematic review. Eur Neuropsychopharmacol. 2019;29:457\u201370.","journal-title":"Eur Neuropsychopharmacol"},{"key":"4253_CR58","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/S0140-6736(25)02365-7","volume":"407","author":"J Schneider-Thoma","year":"2026","unstructured":"Schneider-Thoma J, Zhu Y, Qin M, Dong Y, Guan S, Wang J, et al. Comparative efficacy and tolerability of antidopaminergic and muscarinic antipsychotics for acute schizophrenia: a network meta-analysis of randomised controlled trials indexed in international English and Chinese databases. Lancet. 2026;407:876\u201391.","journal-title":"Lancet"},{"key":"4253_CR59","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.jpsychires.2021.04.032","volume":"138","author":"T Kishi","year":"2021","unstructured":"Kishi T, Ikuta T, Sakuma K, Okuya M, Iwata N. Efficacy and safety of antipsychotic treatments for schizophrenia: A systematic review and network meta-analysis of randomized trials in Japan. J Psychiatr Res. 2021;138:444\u201352.","journal-title":"J Psychiatr Res"},{"key":"4253_CR60","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/s41380-021-01334-4","volume":"27","author":"T Kishi","year":"2022","unstructured":"Kishi T, Ikuta T, Matsuda Y, Sakuma K, Okuya M, Nomura I, et al. Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials. Mol Psychiatry. 2022;27:1136\u201344.","journal-title":"Mol Psychiatry"},{"key":"4253_CR61","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41380-022-01824-z","volume":"28","author":"T Kishi","year":"2023","unstructured":"Kishi T, Ikuta T, Sakuma K, Okuya M, Hatano M, Matsuda Y, et al. Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis. Mol Psychiatry. 2023;28:402\u20139.","journal-title":"Mol Psychiatry"},{"key":"4253_CR62","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S2215-0366(23)00199-2","volume":"10","author":"A Yildiz","year":"2023","unstructured":"Yildiz A, Siafis S, Mavridis D, Vieta E, Leucht S. Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2023;10:693\u2013705.","journal-title":"Lancet Psychiatry"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04253-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04253-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04253-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:02:41Z","timestamp":1790906561000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04253-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4253"],"URL":"https:\/\/doi.org\/10.1038\/s41398-026-04253-6","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"27 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors have no conflicts of interest to declare concerning this study. They also declare any potential competing interests that have arisen in the last 3 years. Prof. Kishi has received speaker\u2019s honoraria from Daiichi Sankyo, Shionogi, Eisai, Janssen, Meiji, Otsuka, Sumitomo, Takeda, Kyowa, Taisho, Boehringer Ingelheim, and Viatris and research grants from Eisai, JSPS KAKENHI (23K06998 and 25K10874), the Japan Agency for Medical Research and Development (JP22dk0307107, JP22wm0525024, 23dk0307117h0001, and 24dk0307129h0001, 256f0137005j0001, 266f0137005j0002, and 276f0137005j0003), and the Japanese Ministry of Health, Labour and Welfare (21GC1018). Dr. Ikuta has nothing to disclose. Dr. Hatano received the speaker\u2019s honoraria from Meiji and Sumitomo, and has received Grant-in-Aid for Early-Career Scientists (23K14827). Dr. Sakuma has received speaker\u2019s honoraria from Janssen, Kyowa, Meiji, Otsuka, Sumitomo, and Takeda and research grants from JSPS KAKENHI (19K17099 and 23K06998) and Japan Agency for Medical Research and Development (JP22dk0307107 and JP23dk0307122). Dr. Takayanagi has nothing to disclose. Prof. Suzuki has received speaker\u2019s honoraria from Eli Lilly and Novo Nordisk. Prof. Iwata has received speaker\u2019s honoraria from Eisai, Janssen, Meiji, Otsuka, Sumitomo, Takeda, Mitsubishi-Tanabe, and Viatris and research grants from Daiichi Sankyo, Eisai, Meiji, Otsuka, Sumitomo, Takeda, Tanabe-Mitsubishi, Grant-in-Aid for Scientific Research (B)(22H03003), and Japan Agency for Medical Research and Development (JP22wm0425008).","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The current study includes a systematic review and meta-analysis based on secondary data from previously published, publicly available data. No new human or animal participants were recruited or studied directly by the authors. This study was performed in accordance with the relevant guidelines and regulations. All studies included in this systematic review and meta-analysis had received ethical approval from their respective institutional review boards, and informed consent was obtained from all participants in those original studies. Therefore, no additional ethical approval or informed consent was required for this study.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"507"}}